Qualification of Drivers; Exemption Applications; Narcolepsy, 21296-21297 [2015-08857]
Download as PDF
21296
Federal Register / Vol. 80, No. 74 / Friday, April 17, 2015 / Notices
exposure limit of 50 ppm for an 8 hour
TWA and the National Institute of
Occupational Safety and Health’s
(NIOSH) permissible exposure limit of
35 ppm for a 10 hour TWA. Under
‘‘worst-case conditions,’’ Ford measured
the CO level to be 17 ppm for the Model
year 2015 Transit, well below the EPA,
OSHA, and NIOSH limits.
Additionally Ford states that it has
internal requirements to establish the
appropriate clearance required between
a vehicle and the ground to meet a
minimum level of on-road functionality.
Ford has specific departure angle
requirements for their vehicle to reduce
tailpipe contact with the ground, curbs,
ramps, etc., during various driving
modes which may result in damage to
the exhaust system that may adversely
affect the exhaust function. Ford
implied that the tailpipe placement
used on its 2015 and future Transitbased passenger vehicles protects the
exhaust system from operational
damage that might expose passengers to
dangerous levels of exhaust gases.
The exemption application would
apply to Model Year 2015 Transit-based
gas bus models (all gross vehicle weight
ratings), vans over 10,000 pounds gross
vehicle weight rating, and
corresponding future Transit-based
production model years. Ford estimates
the annual production of these vehicles
to be similar to the current Ford
Econoline vehicle, which is less than
50,000 vehicles annually.
Ford acknowledges that the exhaust
system location requirements in section
393.83 are intended to ensure that
exhaust gases do not seep into the
passenger compartment of the vehicle.
However, Ford believes that the
performance-based testing that it has
conducted demonstrates that the design
of the exhaust system for the Model
Year 2015 and later Ford Transit CMVs
(1) results in CO exposure limits that are
well below EPA, OSHA, and NIOSH
established thresholds, and (2) will
maintain a level of safety that is
equivalent to the level of safety
achieved without the exemption.
tkelley on DSK3SPTVN1PROD with NOTICES
Request for Comments
In accordance with 49 U.S.C. 31315
and 31136(e), FMCSA requests public
comment from all interested persons on
Ford’s application for an exemption
from 49 CFR 393.83. All comments
received before the close of business on
the comment closing date indicated at
the beginning of this notice will be
considered and will be available for
examination in the docket at the
location listed under the ADDRESSES
section of this notice.
VerDate Sep<11>2014
19:08 Apr 16, 2015
Jkt 235001
Comments received after the comment
closing date will be filed in the public
docket and will be considered to the
extent practicable. In addition to late
comments, FMCSA will continue to file
relevant information in the public
docket that becomes available after the
comment closing date. Interested
persons should continue to examine the
public docket for new material.
Issued on: April 13, 2015.
Larry W. Minor,
Associate Administrator for Policy.
[FR Doc. 2015–08858 Filed 4–16–15; 8:45 am]
BILLING CODE 4910–EX–P
DEPARTMENT OF TRANSPORTATION
Federal Motor Carrier Safety
Administration
[Docket No. FMCSA–2014–0373]
Qualification of Drivers; Exemption
Applications; Narcolepsy
Federal Motor Carrier Safety
Administration (FMCSA), DOT.
ACTION: Notice of applications for
exemption; request for comments.
AGENCY:
FMCSA announces receipt of
applications from three individuals for
an exemption from the prohibitions
against operating a commercial motor
vehicle (CMV) in interstate commerce
by persons with either a clinical
diagnosis of a condition that is likely to
cause a loss of consciousness or any loss
of ability to operate a CMV safely, [49
CFR 391.41(b)(8)], or a mental, nervous,
organic, or functional disease or
psychiatric disorder likely to interfere
with his/her ability to drive a
commercial motor vehicle safely, [49
CFR391.41(b)(9)]. If granted, the
exemption would enable these
individuals who have been diagnosed
with narcolepsy and are receiving
medical treatment to operate CMVs for
2 years in interstate commerce.
DATES: Comments must be received on
or before May 18, 2015.
ADDRESSES: You may submit comments
bearing the Federal Docket Management
System (FDMS) Docket ID FMCSA–
2012–0081 using any of the following
methods:
• Federal eRulemaking Portal: Go to
www.regulations.gov. Follow the on-line
instructions for submitting comments.
• Mail: Docket Management Facility;
U.S. Department of Transportation, 1200
New Jersey Avenue SE., West Building
Ground Floor, Room W12–140,
Washington, DC 20590–0001.
• Hand Delivery or Courier: West
Building Ground Floor, Room W12–140,
SUMMARY:
PO 00000
Frm 00095
Fmt 4703
Sfmt 4703
1200 New Jersey Avenue SE.,
Washington, DC, between 9 a.m. and 5
p.m., Monday through Friday, except
Federal Holidays.
• Fax: 1–202–493–2251.
Each submission must include the
Agency name and the docket ID for this
Notice. Note that DOT posts all
comments received without change to
www.regulations.gov, including any
personal information included in a
comment. Please see the Privacy Act
heading below.
Docket: For access to the docket to
read background documents or
comments, go to www.regulations.gov,
at any time or Room W12–140 on the
ground level of the West Building, 1200
New Jersey Avenue SE., Washington,
DC, between 9 a.m. and 5 p.m., Monday
through Friday, except Federal holidays.
The FDMS is available 24 hours each
day, 365 days each year. If you want
acknowledgment that we received your
comments, please include a selfaddressed, stamped envelope or
postcard or print the acknowledgement
page that appears after submitting
comments on-line.
Privacy Act: In accordance with 5
U.S.C. 553(c), DOT solicits comments
from the public to better inform its
rulemaking process. DOT posts these
comments, without edit, including any
personal information the commenter
provides, to www.regulations.gov, as
described in the system records notice
(DOT/ALL–14 FDMS), which can be
reviewed at www.dot.gov/privacy.
FOR FURTHER INFORMATION CONTACT:
Charles A. Horan, III, Director, Office of
Carrier, Driver and Vehicle Safety, (202)
366–4001, or via email at
fmcsamedical@dot.gov, or by letter to
FMCSA, Room W64–113, Department of
Transportation, 1200 New Jersey
Avenue SE., Washington, DC 20590–
0001. Office hours are from 8:30 a.m. to
5 p.m., Monday through Friday, except
Federal holidays.
SUPPLEMENTARY INFORMATION:
Background
FMCSA has authority under 49 U.S.C.
31136(e) and 31315 to grant exemptions
from certain parts of the Federal Motor
Carrier Safety Regulations. FMCSA must
publish a notice of each exemption
request in the Federal Register [49 CFR
381.315(a)]. The Agency must provide
the public an opportunity to inspect the
information relevant to the application,
including any safety analyses that have
been conducted. The Agency must also
provide an opportunity for public
comment on the request.
The Agency reviews safety analyses
and public comments submitted, and
E:\FR\FM\17APN1.SGM
17APN1
tkelley on DSK3SPTVN1PROD with NOTICES
Federal Register / Vol. 80, No. 74 / Friday, April 17, 2015 / Notices
determines whether granting the
exemption would likely achieve a level
of safety equivalent to, or greater than,
the level that would be achieved by the
current regulation (49 CFR 381.305).
The Agency may grant an exemption
subject to specified terms and
conditions. The decision of the Agency
must be published in the Federal
Register (49 CFR 381.315(b)) with the
reasons for denying or granting the
application and, if granted, the name of
the person or class of persons receiving
the exemption, and the regulatory
provision from which the exemption is
granted. The notice must also specify
the effective period and explain the
terms and conditions of the exemption.
The exemption may be renewed (49 CFR
381.300(b)).
FMCSA provides medical advisory
criteria in the Medical Examination
Report at 49 CFR 391.43 for use by
medical examiners in determining
whether drivers with certain medical
conditions should be certified to operate
commercial motor vehicles in interstate
commerce. The advisory criteria for 49
CFR 391.41(b)(8), indicates that if an
individual has had a sudden episode of
a non-epileptic seizure or loss of
consciousness of unknown cause that
did not require anti-seizure medication,
the decision whether that person’s
condition is likely to cause the loss of
consciousness or loss of ability to
control a CMV should be made on an
individual basis by the medical
examiner in consultation with the
treating physician. Before certification is
considered, it is suggested that a 6month waiting period elapse from the
time of the episode. Following the
waiting period, it is suggested that the
individual have a complete neurological
examination. If the results of the
examination are negative and antiseizure medication is not required, then
the driver may be qualified.
In those individual cases where a
driver had a seizure or an episode of
loss of consciousness that resulted from
a known medical condition (e.g., drug
reaction, high temperature, acute
infectious disease, dehydration, or acute
metabolic disturbance), certification
should be deferred until the driver has
fully recovered from that condition, has
no existing residual complications, and
is not taking anti-seizure medication.
The advisory criteria for 49 CFR
391.41 (b)(9), indicates that a variety of
functional disorders can cause
drowsiness, dizziness, confusion,
weakness or paralysis that may lead to
incoordination, inattention, loss of
functional control and susceptibility to
accidents while driving.
VerDate Sep<11>2014
19:08 Apr 16, 2015
Jkt 235001
Summary of Applications
Thomas Skagen
Mr. Skagen is a 53-year-non-CDL
holder from Washington. He is route
sales representative for a bakery. He was
diagnosed with Narcolepsy without
cataplexy 1 in 2008. His physician has
treated him for 3 years and is supportive
of Mr. Skagen’s exemption request. He
states that Mr. Skagen is treated with
Adderall and has a known 3-year
history of being very compliant with
medical treatment, his Epworth
Sleepiness Scale scores remain within
normal limits, and he does not fall
asleep at any inappropriate times. He
has driven a step van (a walk-in or
multi-stop truck) since 2005 and says
that sleepiness has never been an issue
and in 37 years of driving he has never
caused an accident. He would like to be
granted an exemption in order to obtain
a medical certificate to operate in
interstate commerce.
Charles ‘‘Larry’’ Peterson
Mr. Charles Larry Peterson is a 56year old Class A CDL holder in
Washington. He is tractor-trailer driver.
He was diagnosed with Narcolepsy in
1987 and has been continually treated
for this condition since his diagnosis. A
November 2014 letter from Mr.
Peterson’s physician states he is
successfully treated with Provigil. He
has never known of any traffic
incidents, accidents or problems related
to his narcolepsy or treatment. In his
opinion his narcolepsy is well
controlled and he is safe to drive. A
November 6 letter from his employer
supports Mr. Peterson’s request for an
exemption. The employer reports that
Mr. Peterson has been employed since
2012 and has been an exemplary driver
since he was hired. The employer
reports there have been no accidents,
communication problems, and no
questionable performance issues during
his employment. Mr. Peterson would
like to be granted an exemption to
continue to operate in interstate
commerce.
Stanley Jandreau
Mr. Jandreau is a 43 year old Class A
CDL holder in Maine. A February 2015
letter from his sleep medicine
specialists states that Mr. Jandreau has
been a patient since 2002 when he was
found to have obstructive sleep apnea
and narcolepsy with cataplexy. Mr.
Jandreau’s specialists report that he is
1 According to National Institutes of Health,
National Institute of Neurological Disorders and
Stroke, cataplexy is a sudden loss of muscle tone
while the person is awake that leads to feelings of
weakness and a loss of voluntary muscle control.
PO 00000
Frm 00096
Fmt 4703
Sfmt 4703
21297
stable on therapies for both conditions
and his CPAP compliance is acceptable
to excellent. He is maintained on
Provigil and Zoloft and by all accounts
his sleep disorders are stable and welltreated on his current therapeutic
regimen. Medication or dosing changes
have not been required since [the
specialist] took over his care in 2012.
His specialists support Mr. Jandreau’s
petition for exemption based on his
condition being stable for quite some
time and is not likely to worsen so long
as he continues his current therapeutic
regimen. Mr. Jandreau would like to be
granted an exemption in interstate
commerce.
Request for Comments
In accordance with 49 U.S.C. 31315
and 31136(e), FMCSA requests public
comment from all interested persons on
the applications for exemption
described in this notice. We will
consider all comments received before
the close of business on the closing date
indicated earlier in the notice.
Dated: April 13, 2015.
Larry W. Minor,
Associate Administrator for Policy.
[FR Doc. 2015–08857 Filed 4–16–15; 8:45 am]
BILLING CODE 4910–EX–P
DEPARTMENT OF TRANSPORTATION
Federal Railroad Administration
[Docket Number FRA–2006–24812]
Petition for Waiver of Compliance and
Notice of Public Hearing; Correction
Federal Railroad
Administration, Department of
Transportation.
ACTION: Notice; correction.
AGENCY:
On April 3, 2015 (80 FR
18292), the Federal Railroad
Administration (FRA) provided notice
of a public hearing to receive views,
data, and comments regarding BNSF
Railway’s (BNSF) petition for
modification and extension of its waiver
of compliance from certain provisions of
the Federal railroad safety regulations
contained in title 49 Code of Federal
Regulations part 232, Brake System
Safety Standards for Freight and Other
Non-Passenger Trains and Equipment,
in Docket Number FRA–2006–24812.
The notice contained an incorrect date
of the public hearing.
FOR FURTHER INFORMATION CONTACT:
Steve Zuiderveen, Railroad Safety
Specialist, FRA, 1200 New Jersey
Avenue SE., Washington, DC 20590,
(202) 493–6337,
Steven.Zuiderveen@dot.gov.
SUMMARY:
E:\FR\FM\17APN1.SGM
17APN1
Agencies
[Federal Register Volume 80, Number 74 (Friday, April 17, 2015)]
[Notices]
[Pages 21296-21297]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-08857]
-----------------------------------------------------------------------
DEPARTMENT OF TRANSPORTATION
Federal Motor Carrier Safety Administration
[Docket No. FMCSA-2014-0373]
Qualification of Drivers; Exemption Applications; Narcolepsy
AGENCY: Federal Motor Carrier Safety Administration (FMCSA), DOT.
ACTION: Notice of applications for exemption; request for comments.
-----------------------------------------------------------------------
SUMMARY: FMCSA announces receipt of applications from three individuals
for an exemption from the prohibitions against operating a commercial
motor vehicle (CMV) in interstate commerce by persons with either a
clinical diagnosis of a condition that is likely to cause a loss of
consciousness or any loss of ability to operate a CMV safely, [49 CFR
391.41(b)(8)], or a mental, nervous, organic, or functional disease or
psychiatric disorder likely to interfere with his/her ability to drive
a commercial motor vehicle safely, [49 CFR391.41(b)(9)]. If granted,
the exemption would enable these individuals who have been diagnosed
with narcolepsy and are receiving medical treatment to operate CMVs for
2 years in interstate commerce.
DATES: Comments must be received on or before May 18, 2015.
ADDRESSES: You may submit comments bearing the Federal Docket
Management System (FDMS) Docket ID FMCSA-2012-0081 using any of the
following methods:
Federal eRulemaking Portal: Go to www.regulations.gov.
Follow the on-line instructions for submitting comments.
Mail: Docket Management Facility; U.S. Department of
Transportation, 1200 New Jersey Avenue SE., West Building Ground Floor,
Room W12-140, Washington, DC 20590-0001.
Hand Delivery or Courier: West Building Ground Floor, Room
W12-140, 1200 New Jersey Avenue SE., Washington, DC, between 9 a.m. and
5 p.m., Monday through Friday, except Federal Holidays.
Fax: 1-202-493-2251.
Each submission must include the Agency name and the docket ID for
this Notice. Note that DOT posts all comments received without change
to www.regulations.gov, including any personal information included in
a comment. Please see the Privacy Act heading below.
Docket: For access to the docket to read background documents or
comments, go to www.regulations.gov, at any time or Room W12-140 on the
ground level of the West Building, 1200 New Jersey Avenue SE.,
Washington, DC, between 9 a.m. and 5 p.m., Monday through Friday,
except Federal holidays. The FDMS is available 24 hours each day, 365
days each year. If you want acknowledgment that we received your
comments, please include a self-addressed, stamped envelope or postcard
or print the acknowledgement page that appears after submitting
comments on-line.
Privacy Act: In accordance with 5 U.S.C. 553(c), DOT solicits
comments from the public to better inform its rulemaking process. DOT
posts these comments, without edit, including any personal information
the commenter provides, to www.regulations.gov, as described in the
system records notice (DOT/ALL-14 FDMS), which can be reviewed at
www.dot.gov/privacy.
FOR FURTHER INFORMATION CONTACT: Charles A. Horan, III, Director,
Office of Carrier, Driver and Vehicle Safety, (202) 366-4001, or via
email at fmcsamedical@dot.gov, or by letter to FMCSA, Room W64-113,
Department of Transportation, 1200 New Jersey Avenue SE., Washington,
DC 20590-0001. Office hours are from 8:30 a.m. to 5 p.m., Monday
through Friday, except Federal holidays.
SUPPLEMENTARY INFORMATION:
Background
FMCSA has authority under 49 U.S.C. 31136(e) and 31315 to grant
exemptions from certain parts of the Federal Motor Carrier Safety
Regulations. FMCSA must publish a notice of each exemption request in
the Federal Register [49 CFR 381.315(a)]. The Agency must provide the
public an opportunity to inspect the information relevant to the
application, including any safety analyses that have been conducted.
The Agency must also provide an opportunity for public comment on the
request.
The Agency reviews safety analyses and public comments submitted,
and
[[Page 21297]]
determines whether granting the exemption would likely achieve a level
of safety equivalent to, or greater than, the level that would be
achieved by the current regulation (49 CFR 381.305). The Agency may
grant an exemption subject to specified terms and conditions. The
decision of the Agency must be published in the Federal Register (49
CFR 381.315(b)) with the reasons for denying or granting the
application and, if granted, the name of the person or class of persons
receiving the exemption, and the regulatory provision from which the
exemption is granted. The notice must also specify the effective period
and explain the terms and conditions of the exemption. The exemption
may be renewed (49 CFR 381.300(b)).
FMCSA provides medical advisory criteria in the Medical Examination
Report at 49 CFR 391.43 for use by medical examiners in determining
whether drivers with certain medical conditions should be certified to
operate commercial motor vehicles in interstate commerce. The advisory
criteria for 49 CFR 391.41(b)(8), indicates that if an individual has
had a sudden episode of a non-epileptic seizure or loss of
consciousness of unknown cause that did not require anti-seizure
medication, the decision whether that person's condition is likely to
cause the loss of consciousness or loss of ability to control a CMV
should be made on an individual basis by the medical examiner in
consultation with the treating physician. Before certification is
considered, it is suggested that a 6-month waiting period elapse from
the time of the episode. Following the waiting period, it is suggested
that the individual have a complete neurological examination. If the
results of the examination are negative and anti-seizure medication is
not required, then the driver may be qualified.
In those individual cases where a driver had a seizure or an
episode of loss of consciousness that resulted from a known medical
condition (e.g., drug reaction, high temperature, acute infectious
disease, dehydration, or acute metabolic disturbance), certification
should be deferred until the driver has fully recovered from that
condition, has no existing residual complications, and is not taking
anti-seizure medication.
The advisory criteria for 49 CFR 391.41 (b)(9), indicates that a
variety of functional disorders can cause drowsiness, dizziness,
confusion, weakness or paralysis that may lead to incoordination,
inattention, loss of functional control and susceptibility to accidents
while driving.
Summary of Applications
Thomas Skagen
Mr. Skagen is a 53-year-non-CDL holder from Washington. He is route
sales representative for a bakery. He was diagnosed with Narcolepsy
without cataplexy \1\ in 2008. His physician has treated him for 3
years and is supportive of Mr. Skagen's exemption request. He states
that Mr. Skagen is treated with Adderall and has a known 3-year history
of being very compliant with medical treatment, his Epworth Sleepiness
Scale scores remain within normal limits, and he does not fall asleep
at any inappropriate times. He has driven a step van (a walk-in or
multi-stop truck) since 2005 and says that sleepiness has never been an
issue and in 37 years of driving he has never caused an accident. He
would like to be granted an exemption in order to obtain a medical
certificate to operate in interstate commerce.
---------------------------------------------------------------------------
\1\ According to National Institutes of Health, National
Institute of Neurological Disorders and Stroke, cataplexy is a
sudden loss of muscle tone while the person is awake that leads to
feelings of weakness and a loss of voluntary muscle control.
---------------------------------------------------------------------------
Charles ``Larry'' Peterson
Mr. Charles Larry Peterson is a 56-year old Class A CDL holder in
Washington. He is tractor-trailer driver. He was diagnosed with
Narcolepsy in 1987 and has been continually treated for this condition
since his diagnosis. A November 2014 letter from Mr. Peterson's
physician states he is successfully treated with Provigil. He has never
known of any traffic incidents, accidents or problems related to his
narcolepsy or treatment. In his opinion his narcolepsy is well
controlled and he is safe to drive. A November 6 letter from his
employer supports Mr. Peterson's request for an exemption. The employer
reports that Mr. Peterson has been employed since 2012 and has been an
exemplary driver since he was hired. The employer reports there have
been no accidents, communication problems, and no questionable
performance issues during his employment. Mr. Peterson would like to be
granted an exemption to continue to operate in interstate commerce.
Stanley Jandreau
Mr. Jandreau is a 43 year old Class A CDL holder in Maine. A
February 2015 letter from his sleep medicine specialists states that
Mr. Jandreau has been a patient since 2002 when he was found to have
obstructive sleep apnea and narcolepsy with cataplexy. Mr. Jandreau's
specialists report that he is stable on therapies for both conditions
and his CPAP compliance is acceptable to excellent. He is maintained on
Provigil and Zoloft and by all accounts his sleep disorders are stable
and well-treated on his current therapeutic regimen. Medication or
dosing changes have not been required since [the specialist] took over
his care in 2012. His specialists support Mr. Jandreau's petition for
exemption based on his condition being stable for quite some time and
is not likely to worsen so long as he continues his current therapeutic
regimen. Mr. Jandreau would like to be granted an exemption in
interstate commerce.
Request for Comments
In accordance with 49 U.S.C. 31315 and 31136(e), FMCSA requests
public comment from all interested persons on the applications for
exemption described in this notice. We will consider all comments
received before the close of business on the closing date indicated
earlier in the notice.
Dated: April 13, 2015.
Larry W. Minor,
Associate Administrator for Policy.
[FR Doc. 2015-08857 Filed 4-16-15; 8:45 am]
BILLING CODE 4910-EX-P